Cargando…
B-Cell Depletion Therapy in Systemic Sclerosis: Experimental Rationale and Update on Clinical Evidence
Systemic sclerosis (SSc) is a systemic rheumatic disease with poor prognosis since therapeutic options are limited. Recent evidence from animal models suggests that B-cells may be actively involved in the fibrotic process. B-cells from tight skin mice, an animal model of scleroderma, display a “hype...
Autores principales: | Daoussis, Dimitrios, Liossis, Stamatis-Nick C., Yiannopoulos, Georgios, Andonopoulos, Andrew P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3150146/ https://www.ncbi.nlm.nih.gov/pubmed/21826145 http://dx.doi.org/10.1155/2011/214013 |
Ejemplares similares
-
B-cell depletion therapy in patients with diffuse systemic sclerosis associates with a significant decrease in PDGFR expression and activation in spindle-like cells in the skin
por: Daoussis, Dimitrios, et al.
Publicado: (2012) -
B cell depletion therapy upregulates Dkk-1 skin expression in patients with systemic sclerosis: association with enhanced resolution of skin fibrosis
por: Daoussis, Dimitrios, et al.
Publicado: (2016) -
Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study
por: Daoussis, Dimitrios, et al.
Publicado: (2010) -
Treatment of systemic sclerosis associated fibrotic manifestations: Current options and future directions
por: Daoussis, Dimitrios, et al.
Publicado: (2019) -
Calcified lymph nodes and systemic sclerosis
por: Angelopoulou, Fotini, et al.
Publicado: (2018)